Divi's Laboratories Limited (DIVISLAB.NS)
- Previous Close
3,931.15 - Open
3,887.05 - Bid --
- Ask --
- Day's Range
3,870.00 - 3,965.00 - 52 Week Range
3,051.00 - 4,100.00 - Volume
31,964 - Avg. Volume
507,193 - Market Cap (intraday)
1.043T - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
75.54 - EPS (TTM)
52.01 - Earnings Date May 18, 2024 - May 22, 2024
- Forward Dividend & Yield 30.00 (0.77%)
- Ex-Dividend Date Aug 11, 2023
- 1y Target Est
4,951.17
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.
www.divislabs.com8,433
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: DIVISLAB.NS
Performance Overview: DIVISLAB.NS
Trailing total returns as of 5/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIVISLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIVISLAB.NS
Valuation Measures
Market Cap
1.04T
Enterprise Value
1.00T
Trailing P/E
75.05
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.04
Price/Book (mrq)
8.19
Enterprise Value/Revenue
13.56
Enterprise Value/EBITDA
43.81
Financial Highlights
Profitability and Income Statement
Profit Margin
18.46%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
74.93B
Net Income Avi to Common (ttm)
13.83B
Diluted EPS (ttm)
52.01
Balance Sheet and Cash Flow
Total Cash (mrq)
36.11B
Total Debt/Equity (mrq)
0.04%
Levered Free Cash Flow (ttm)
--
Research Analysis: DIVISLAB.NS
Company Insights: DIVISLAB.NS
DIVISLAB.NS does not have Company Insights